Status:
COMPLETED
A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Juvenile Idiopathic Arthritis
Eligibility:
All Genders
12+ years
Brief Summary
This study will determine the incidences of infections and malignancies among JIA patients treated with abatacept
Eligibility Criteria
Inclusion
- Two diagnoses of JIA (ICD-9 code 714.3x) within 90 days
- Age less than 18 years at the time of second of the two diagnoses
- Index date is the date of initiating treatment with abatacept
Exclusion
- Greater than or equal to 18 years of age
Key Trial Info
Start Date :
July 12 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2016
Estimated Enrollment :
264 Patients enrolled
Trial Details
Trial ID
NCT03769558
Start Date
July 12 2016
End Date
September 30 2016
Last Update
March 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Princeton, New Jersey, United States, 08540